Notícias

While the market focuses on a single class of blockbuster drugs, a different story is unfolding inside the company. Lilly’s immunology, oncology, and neuroscience medicines are quietly compounding at a blistering pace. These other therapeutic areas collectively grew by 160% last quarter, a rate that suggests a much broader growth engine is taking shape.

While many investors focus on a slowdown in one business segment, they may be overlooking the remarkable growth occurring in another.

Merck snagged the first-ever approval for a PCSK9 pill to lower LDL cholesterol, starting a new rivalry with injection-makers.

The pharma division is firing on all cylinders, but a sudden crack in the MedTech business has the market worried about the company's new two-part growth plan.

It’s the first pill that lowers blood cholesterol far better than statins—medicines that a quarter of adults take to reduce their risk of heart attack and stroke.

Lipfendra, to be taken once a day, is designed to help lower cholesterol levels beyond what statins alone can achieve.

It’s the first pill that lowers blood cholesterol far better than statins—medicines that a quarter of adults take to reduce their risk of heart attack and stroke.

The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former commissioner Marty Makary.

Johnson and Johnson has quietly become one of the best-performing mega-caps of the past year, but with a fresh pullback and a pipeline firing on multiple cylinders, the bigger question is whether the next leg higher finally breaks through to record territory.

Merck stock popped Wednesday on the back of positive test results for a new treatment combo in a common form of lung cancer.

(Updates with economic data, recent oil price movement, world markets' overview and corporate stock

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1%, and the actively tra

Merck (NYSE:MRK) received FDA approval for expanded use of Keytruda and Keytruda QLEX combinations with Padcev in muscle-invasive bladder cancer. The decision is based on results from the pivotal Phase 3 KEYNOTE-B15 study. This is the first PD-1 inhibitor plus antibody drug conjugate regimen cleared for these patients regardless of cisplatin eligibility. The latest approval adds another indication for Merck's flagship oncology drug Keytruda. It reinforces the company’s presence in bladder...

Stock Market Today: The Dow Jones index wavered Wednesday ahead of key inflation data. ASML stock jumped on earnings.

The results were seen by Wall Street analysts as “direct proof-of-concept” that sac-TMT, a drug Merck views as a “cornerstone,” could be part of a future treatment standard for front-line lung cancer.

In the world of big pharma, one company is both the star performer and the most expensive name on the marquee, forcing investors to ask if the price of admission is simply too high.

Johnson and Johnson just raised its full-year outlook toward a historic $100 billion revenue target, yet the stock still trades well below where our model says it should be. The real question is whether the pipeline can outrun the headwinds closing in fast.

The company attributed the guidance cut to a larger-than-expected shift in payer mix and a greater financial impact from health insurance exchanges.

PFE's oncology business is in focus ahead of Q2 results as growth from key cancer drugs, biosimilars and pipeline updates may offset declines in older therapies.

BMY's FDA filing for mezigdomide in relapsed or refractory multiple myeloma marks another step in advancing its protein degrader pipeline.

Merck & Co. is expected to announce its second-quarter earnings in August, and Wall Street forecasts a double-digit decline in its profits.

Eli Lilly has whipsawed shareholders in 2026, but one under-the-radar catalyst in its pipeline could change the trajectory entirely. Here is what the bulls are watching that most investors are still sleeping on.

For investors seeking exposure to biotechnology's future, Incyte presents a clearer forward picture of accelerating growth, while the larger Regeneron asks for more faith in its pipeline.

Merck's Keytruda in combination with Pfizer's Padcev wins FDA nod for expanded use in muscle-invasive bladder cancer, regardless of cisplatin eligibility.

At $1,189, Eli Lilly (LLY) looks set up for roughly 76% of upside over the next three years under a conservative scenario. That is a move large enough to justify digging into where it comes from. Revenue compounding does the work, but the multiple takes a meaningful cut along the way. Here is the operational reality the math is built on.

Merck stock has delivered an 87.4% return over the past 5 years. The current Discounted Cash Flow (DCF) estimate now points to meaningful upside relative to the US$123.54 share price, while the broader valuation checks paint a more mixed picture. Over 5 years, Merck has returned 87.4%. This puts current buyers in the position of judging whether that past compounding already reflects much of the company’s progress. Ongoing expansion of the Keytruda and broader oncology pipeline may support...

SLS leads in stock momentum, while MLTX is cheaper and better-funded, with nearly $300 million in cash at the end of the first quarter.

U.S. Central Command said that American forces had begun launching further strikes against Iran to thwart their ability “to attack civilian mariners and commercial ships freely transiting the Strait of Hormuz.”

In the closing of the recent trading day, Merck (MRK) stood at $123.54, denoting a -1.22% move from the preceding trading day.

This healthcare giant is on a serious run, but for investors arriving now, the question is whether the price of admission already includes the victory lap.